Un trastorno que puede ser un importante desafío clínico | 13 SEP 22

Actualización sobre la polimialgia reumática

En general, el pronóstico de la PMR es bueno y la enfermedad se cura en algunos años, durante los cuales se debe indicar glucocorticoides para controlar la enfermedad y sus síntomas
Autor/a: I. Lundberg, A. Sharma, C. Turesson y A. Mohammad Journal of Internal Medicine, 2022, 00; 116
INDICE:  1. Texto principal | 2. Referencia bibliográfica
Referencia bibliográfica

1 Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res (Hoboken). 2017; 69: 1282– 5.

2 Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol. 2002; 29: 1694– 7.

3 Michet CJ, Matteson EL. Polymyalgia rheumatica. BMJ. 2008; 336: 765– 9.

4 Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009; 61: 1454– 61.

5 Noltorp S, Svensson B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol. 1991; 9: 351– 5.

6 Schaufelberger C, Bengtsson B-Å, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol. 1995; 34: 261– 4.

7 Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94. J Rheumatol. 1997; 24: 1739– 43.

8 Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017; 47: 253– 6.

9 Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995; 123: 192– 4.

10 Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020; 50: 1040– 8.

11 Kim IY, Seo GH, Lee S, Jeong H, Kim H, Lee J, et al. Epidemiology of polymyalgia rheumatica in Korea. J Rheum Dis. 2014; 21: 297– 302.

12 Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003; 49: 594– 8.

13 Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol. 2000; 18: S9– 11.

14 Cimmino MA. Genetic and environmental factors in polymyalgia rheumatica. Ann Rheum Dis. 1997; 56: 576– 7.

15 Metyas S, Chen C, Aung T, Ballester A, Cheav S. Rheumatologic manifestations of post SARS-CoV-2 infection: a case series. Curr Rheumatol Rev. 2022. https://doi.org/10.2174/1573397118666220211155716

16 Mettler C, Jonville-Bera A-P, Grandvuillemin A, Treluyer J-M, Terrier B, Chouchana L. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology (Oxford). 2022; 61: 865– 7.

17 Hysa E, Sobrero A, Camellino D, Rumi F, Carrara G, Cutolo M, et al. A seasonal pattern in the onset of polymyalgia rheumatica and giant cell arteritis? A systematic review and meta-analysis. Semin Arthritis Rheum. 2020; 50: 1131– 9.

18 Sobrero A, Paolino S, Hysa E, Camellino D, Tomatis V, Cutolo M, et al. Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single centre. Clin Exp Rheumatol. 2021; 39: 564– 9.

19 Peris P. Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection. J Rheumatol. 2003; 30: 2624– 6.

20 Liozon E, Parreau S, Filloux M, Dumonteil S, Gondran G, Bezanahary H, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review. Autoimmun Rev. 2021; 20:102732.

21 Izuka S, Komai T, Natsumoto B, Shoda H, Fujio K. Self-limited polymyalgia rheumatica-like syndrome following mRNA-1273 SARS-CoV-2 vaccination. Intern Med. 2022; 61: 903– 6.

22 Cadiou S, Perdriger A, Ardois S, Albert J-D, Berthoud O, Lescoat A, et al. SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” by Manzo Joint Bone Spine 2021;88:105150. Joint Bone Spine. 2022; 89:105282.

23 Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri C, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum. 1996; 39: 1199– 207.

24 Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, et al. Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum. 2000; 43: 2472– 80.

25 Meliconi R, Pulsatelli L, Melchiorri C, Frizziero L, Salvarani C, Macchioni P, et al. Synovial expression of cell adhesion molecules in polymyalgia rheumatica. Clin Exp Immunol. 1997; 107: 494– 500.

26 Pulsatelli L, Dolzani P, Silvestri T, De Giorgio R, Salvarani C, Macchioni P, et al. Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica. Clin Exp Rheumatol. 2006; 24: 562– 6.

27 Ruta S, Rosa J, Navarta DA, Saucedo C, Catoggio LJ, Monaco RG, et al. Ultrasound assessment of new onset bilateral painful shoulder in patients with polymyalgia rheumatica and rheumatoid arthritis. Clin Rheumatol. 2012; 31: 1383– 7.

28 Owen CE, Poon AMT, Yang V, Mcmaster C, Lee ST, Liew DFL, et al. Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity. Eur J Nucl Med Mol Imaging. 2020; 47: 2461– 8.

29 Shintani S, Shiigai T, Matsui Y. Polymyalgia rheumatica (PMR): clinical, laboratory, and immunofluorescence studies in 13 patients. Clin Neurol Neurosurg. 2002; 104: 20– 9.

30 Uddhammar A, Rantapaa Dahlqvist S, Hedberg B, Thornell LE. Deltoid muscle in patients with polymyalgia rheumatica. J Rheumatol. 1998; 25: 1344– 51.

31 Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993; 36: 1286– 94.

32 Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017; 16: 833– 44.

33 Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P, et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum. 2008; 59: 1147– 54.

34 Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013; 9: 731– 40.

35 Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994; 121: 484– 91.

36 Carvajal Alegria G, Boukhlal S, Cornec D, Devauchelle-Pensec V. The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun Rev. 2020; 19:102670.

37 Van Sleen Y, Wang Q, Van Der Geest KSM, Westra J, Abdulahad WH, Heeringa P, et al. Involvement of monocyte subsets in the immunopathology of giant cell arteritis. Sci Rep. 2017; 7: 6553.

38 Hysa E, Gotelli E, Sammorì S, Cimmino MA, Paolino S, Pizzorni C, et al. Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev. 2022; 21:102995.

39 Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Liang K, Melander O, et al. Body mass index and the risk of giant cell arteritis: results from a prospective study. Rheumatology (Oxford). 2015; 54: 433– 40.

40 Wadström K, Jacobsson L, Mohammad AJ, Warrington KJ, Matteson EL, Turesson C. Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatology (Oxford). 2020; 59: 3229– 36.

41 Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008; 372: 234– 45.

42 Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol. 2004; 18: 705– 22.

43 Nesher G. Polymyalgia rheumatica—diagnosis and classification. J Autoimmun. 2014; 48–49: 76– 8.

44 Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013; 381: 63– 72.

45 Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N. “I suddenly felt I'd aged”: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns. 2015; 98: 645– 50.

46 Salvarani C, Gabriel SE, Michael O'fallon W, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum. 1995; 38: 369– 73.

47 Hamrin B, Jonsson N, Hellsten S. “Polymyalgia arteritica”. Further clinical and histopathological studies with a report of six autopsy cases. Ann Rheum Dis. 1968; 27: 397– 405.

48 Schmidt WA, Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology (Oxford). 2002; 41: 46– 52.

49 Baldursson Ó, Steinsson K, Björnsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis and Rheumatism. 1994; 37: 1007– 12.

50 Gonzalez-Gay MA, García-Porrúa C. Systemic vasculitis in adults in northwestern Spain, 1988–1997. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999; 78: 292– 308.

51 Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015; 42: 1213– 7.

52 Nobunaga M, Yoshioka K, Yasuda M, Shingu M. Clinical studies of polymyalgia rheumatica. A proposal of diagnostic criteria. Jpn J Med. 1989; 28: 452– 6.

53 Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979; 38: 434– 9.

54 Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984; 13: 322– 8.

55 Hamrin B. Polymyalgia arteritica. Acta Med Scand Suppl. 1972; 533: 1– 131.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022